A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2028

Study Completion Date

August 1, 2031

Conditions

Small Cell Lung Cancer

Interventions

DRUG

IBB0979

bifunctional antibody-cytokine fusion protein that targets B7-H3 and IL-10 receptor

DRUG

topotecan hydrochloride for injection

Topotecan hydrochloride will be administered intravenously per prescribing information.

All Listed Sponsors

collaborator

The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital

UNKNOWN

lead

SUNHO（China）BioPharmaceutical CO., Ltd.

INDUSTRY